Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
136.1 CHF | +6.20% |
|
-.--% | -.--% |
01/07 | Zimmer Biomet Shares Fall Following Piper Sandler Downgrade | MT |
01/07 | Piper Sandler Downgrades Zimmer Biomet to Neutral From Overweight, Adjusts Price Target to $115 From $140 | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's enterprise value to sales, at 3.37 times its current sales, is high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 2.18TCr | - | ||
-6.24% | 18TCr | C+ | ||
-6.39% | 9.89TCr | C | ||
-5.97% | 6.63TCr | A | ||
-9.61% | 4.46TCr | B- | ||
+8.84% | 4.4TCr | B- | ||
+10.13% | 4.01TCr | B+ | ||
+12.69% | 2.92TCr | B | ||
+13.33% | 2.34TCr | A- | ||
-7.83% | 2.36TCr | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZBH Stock
- 0QQD Stock
- Ratings Zimmer Biomet Holdings, Inc.